Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis
A live, multi-source view of Rocket Pharmaceuticals, Inc. (RCKT): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Sector: Healthcare · Industry: Biotechnology · United States · 202 employees · rocketpharma.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Rocket Pharmaceuticals, Inc. (RCKT) had a market capitalization of $423.7M (forward -3.0) and a beta of 0.50; the shares traded in a 52-week range of $2.53 – $5.45 (16.3% over the year).
- Market cap
- $423.7M
- Enterprise value
- $164.8M
- Forward P/E
- -3.0
- Price / book
- 1.15
- EPS (trailing)
- $-0.17
- EPS (forward)
- $-1.30
- Payout ratio
- 0.0%
- 52-week range
- $2.53 – $5.45
- 52-week change
- 16.3%
- Beta
- 0.50
- Average volume
- 2.1M
- Shares outstanding
- 109.8M
- Short % of float
- 16.07%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Rocket Pharmaceuticals, Inc. (RCKT) last closed at $3.48 (the last completed close before that scan).
Technicals at the scan: RSI 46 (neutral territory), price -3.9% versus its 20-day average, 20-day versus 50-day average spread +1.4%, MACD histogram -0.02.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 55/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of RCKT; corporate insiders filed 0 buys and 4 sells (2 distinct filers, latest disclosure 2026-08-20). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Gaurav Shah (0B/2S), Martin Wilson (0B/2S). Who is trading what
RapidTradeView pick record
RCKT has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Rocket Pharmaceuticals, Inc. (RCKT) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RCKT.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.